Gemphire Therapeutics

$0.4581
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0045 (-0.97%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell GEMP and other stocks, options, ETFs, and crypto commission-free!

About GEMP

Gemphire Therapeutics Inc. Common Stock, also called Gemphire Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics of dyslipidemia, as well as non-alcoholic fatty liver disease. Read More It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI.

Employees
9
Headquarters
Livonia, Michigan
Founded
2014
Market Cap
6.81M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
80.23K
High Today
$0.4668
Low Today
$0.4461
Open Price
$0.4578
Volume
32.06K
52 Week High
$2.52
52 Week Low
$0.4211

Collections

GEMP Earnings

-$0.66
-$0.51
-$0.35
-$0.20
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 7, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.